11.03.2014 • News

Brenntag names Anthony Gerace to lead global Mergers & Acquisitions for Brenntag Group

Brenntag announces that Anthony Gerace will be promoted to Managing Director Mergers & Acquisitions for the Group, effective March 1, 2014.

In this new position Anthony Gerace will lead the Group's Mergers & Acquisitions team to focus on further expansion, in line with Brenntag's strategy. Anthony Gerace will report to Steven Holland, Chief Executive Officer.

Anthony Gerace joined Brenntag in 1993 and is currently responsible for Mergers & Acquisitions activities in the Brenntag North American organization. During his tenure with the company he has accumulated significant expertise in successfully managing operating companies in addition to directing strategic Mergers & Acquisitions projects for Brenntag in North America.

Brenntag Group's Chief Executive Officer Steven Holland: "I'm delighted to announce the appointment of Anthony Gerace as Managing Director Mergers & Acquisitions. He is singularly qualified for this role. As a knowledgeable professional in this field, he brings especially strong expertise in the Mergers & Acquisitions sphere and will support Brenntag's already successful track record in this important area." 

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read